Spexis Funding Round

8/15/2023

Venture Equity

$2,500,000

Undisclosed

A clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology. This new capital allows us to not only initiate the COPILOT study in the third quarter, but will also allow for continued progress across start-up activities for COPA, the second part of our planned pivotal efficacy and safety Phase 3 study.

Private & Independent

Biopharmaceutical

Hegenheimermattweg 125
Allschwil, CH-4123
CH

Spexis is generating hope for rare disease & oncology patients by targeting critical unmet treatment needs and difficult-to-drug structures. Spexis AG (SIX:SPEX) is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancer. The most advanced of our four clinical candidates (Phases 1-3) is ColiFin®, an inhaled therapeutic for cystic fibrosis, is already approved and marketed in Europe and will be entering global pivotal P3 studies in early 2023. Furthermore, we apply our leading macrocyclic technology platform, the result of more than 25 years and $400 million of cumulative research and investment, to discover promising therapeutic candidates that can target difficult-to-drug structures. With our pipeline of potentially transformative product candidates, we aim to deliver substantial benefits to patients and meaningful value to society and our stakeholders.